Last reviewed · How we verify
Ferric Carboxymaltose Injectable Product
At a glance
| Generic name | Ferric Carboxymaltose Injectable Product |
|---|---|
| Also known as | Ferinject |
| Sponsor | Royal Centre for Defence Medicine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome (PHASE4)
- Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants (PHASE1)
- Effect of IV Iron in Patients With Heart Failure With Preserved Ejection Fraction (PHASE4)
- Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia (PHASE1)
- Comparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia (PHASE4)
- Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency (PHASE2)
- Impact of Intravenous Iron on Musculoskeletal Function in Older Adults (PHASE4)
- Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: